AA
NKGN

AQR Arbitrage’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

AQR Arbitrage’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-70,000
Closed -$709K – 937
2023
Q1 		$709K Hold
70,000
– – 0.02% 468
2022
Q4 		$697K Buy
70,000
+35,000
+100% +$346K 0.02% 563
2022
Q3 		$341K Buy
35,000
+22,000
+169% +$215K 0.01% 728
2022
Q2 		$126K Hold
13,000
– – ﹤0.01% 809
2022
Q1 		$126K Hold
13,000
– – ﹤0.01% 754
2021
Q4 		$126K Sell
13,000
-274,640
-95% -$2.67M ﹤0.01% 1174
2021
Q3 		$2.79M Buy
+287,640
New +$2.8M 0.08% 216

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

AQR Arbitrage's NKGN Position: Q2 2023 in Review

AQR Arbitrage sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 70,000 shares — an estimated $709K sold.

AQR Arbitrage first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $2.79M in Q3 2021. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • AQR Arbitrage reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • AQR Arbitrage sold 70,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $709K.
  • AQR Arbitrage first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • AQR Arbitrage's NKGen Biotech, Inc. Common Stock position peaked at $2.79M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on AQR Arbitrage's 13F filing for Q2 2023, filed 14 Aug 2023.